Jatenzo Dosing for Older Adults (50, 64): What Men Need to Know

Why Jatenzo Dosing Matters More After 50

Men between 50 and 64 sit at the intersection of declining androgen levels and rising cardiovascular, metabolic, and hepatic risk. Choosing the right testosterone formulation and dose is not a one-size decision. Age-specific physiology changes how the drug is absorbed, metabolized, and cleared.

Jatenzo (testosterone undecanoate) earned FDA approval in March 2019 as the first oral testosterone replacement therapy for adult men with hypogonadism caused by specific medical conditions 1. Unlike older oral androgens such as methyltestosterone, testosterone undecanoate is absorbed through the intestinal lymphatic system, bypassing first-pass hepatic metabolism. This mechanism reduces the hepatotoxicity that historically made oral testosterone a poor choice 2.

For older adults, the lymphatic absorption pathway offers a practical advantage. Men aged 50 to 64 are more likely to be on hepatically metabolized medications (statins, metformin, antihypertensives), so avoiding additional liver burden matters. The 2018 Endocrine Society Clinical Practice Guideline recommends that clinicians "assess the risk of testosterone therapy in men with conditions that may be exacerbated by testosterone" before initiating treatment 3. That guidance is especially relevant in this age group, where baseline risks are neither negligible nor prohibitive.

Starting Dose: 237 mg Twice Daily

Every man initiating Jatenzo, regardless of age, begins at 237 mg taken orally twice daily. Each dose must accompany a meal with adequate fat content. This is non-negotiable pharmacology.

The FDA label specifies a starting dose of 237 mg (one capsule) twice daily, taken with food 1. The fat in the meal triggers chylomicron formation in the intestinal epithelium, which carries the testosterone undecanoate into the lymphatic system. Without dietary fat, absorption drops significantly, and serum testosterone levels may fail to reach the therapeutic range. A meal containing approximately 15 to 30 grams of fat is sufficient. Breakfast with eggs and avocado or lunch with a salad dressed in olive oil both meet this threshold.

For men aged 50 to 64, morning appetite often declines, and some skip breakfast altogether. Skipping or eating a low-fat meal can reduce Jatenzo bioavailability by 40 to 50%, effectively underdosing the patient 4. Clinicians should discuss meal timing and composition at the first prescribing visit, because poor adherence to the food requirement is the most common reason for subtherapeutic levels in practice.

Titration: How and When to Adjust

Dose adjustments happen based on a single measured value: serum total testosterone drawn approximately one month after starting therapy. The timing matters.

According to the Jatenzo prescribing information, serum testosterone should be measured after approximately one month of therapy, ideally as a trough level drawn in the morning before the daily dose 1. Titration follows a stepwise algorithm:

• If serum T is below 300 ng/dL, increase the dose by one capsule strength (e.g., from 237 mg to 316 mg twice daily, or from 316 mg to 396 mg twice daily).
• If serum T exceeds 1 to 050 ng/dL, decrease by one capsule strength (e.g., from 237 mg to 198 mg, or from 198 mg to 158 mg twice daily).
• If serum T falls between 300 and 1 to 050 ng/dL, maintain the current dose.

The minimum effective dose is 158 mg twice daily. The maximum is 396 mg twice daily. If a man on 396 mg twice daily still fails to reach 300 ng/dL, the prescribing information recommends considering an alternative testosterone formulation 1.

In the key phase 3 trial by Swerdloff and colleagues, 87% of men achieved a serum testosterone within the eugonadal range (300 to 1 to 000 ng/dL) at three months 2. The trial enrolled men aged 18 to 65, with a mean age of approximately 54, making its data directly applicable to the 50-to-64 cohort.

Cardiovascular Monitoring in the 50-to-64 Window

Blood pressure elevation is Jatenzo's most clinically significant boxed warning. Men in this age range already carry higher baseline cardiovascular risk, making monitoring a priority rather than an afterthought.

The FDA issued a boxed warning for Jatenzo regarding the potential for blood pressure increases 1. In clinical trials, systolic blood pressure increased by a mean of 3 to 5 mmHg, and diastolic by 2 to 3 mmHg. While these numbers seem small in aggregate, they can be clinically meaningful in a 58-year-old man already on an ACE inhibitor with a resting systolic of 138.

The prescribing information recommends measuring blood pressure at baseline, at periodic intervals during treatment, and on every dose adjustment 1. If blood pressure rises above 140/90 mmHg on two separate occasions, clinicians should reassess whether continuing Jatenzo is appropriate. The TRAVERSE trial (N=5,246), the largest randomized cardiovascular safety trial of testosterone therapy, found that testosterone replacement did not significantly increase the incidence of major adverse cardiovascular events (MACE) compared to placebo in men aged 45 to 80 with hypogonadism and established or high risk for cardiovascular disease (HR 0.99; 95% CI 0.81 to 1.21) 5. Dr. Shalender Bhasin, the TRAVERSE principal investigator, stated that the findings "provide reassurance that testosterone replacement therapy in middle-aged and older men with hypogonadism does not increase the short-to-intermediate term risk of major adverse cardiac events" 5.

That reassurance is qualified. TRAVERSE used a topical gel, not oral testosterone undecanoate. The blood pressure effects seen with Jatenzo's lymphatic absorption route are pharmacologically distinct. Until a dedicated cardiovascular outcomes trial with Jatenzo is completed, clinicians should monitor BP and manage it aggressively in this age bracket.

Hematocrit: The Silent Risk

Polycythemia (hematocrit above 54%) is a class effect of all testosterone formulations, and it becomes more clinically relevant in men over 50 who may already have elevated baseline values.

The Endocrine Society guideline recommends checking hematocrit at baseline, at 3 to 6 months after initiating testosterone therapy, and then annually 3. If hematocrit exceeds 54%, the guideline advises stopping testosterone until it falls below 50%, then restarting at a lower dose. In the Swerdloff trial, the incidence of hematocrit above 54% was 3.9% among Jatenzo-treated patients 2.

Men between 50 and 64 living at higher altitudes, those with obstructive sleep apnea, or those with chronic lung disease are predisposed to higher baseline hematocrit. A 60-year-old man with untreated sleep apnea and a baseline hematocrit of 50% is already approaching the threshold. Starting testosterone without screening for and treating contributing factors creates preventable risk.

A practical approach: order a CBC with hematocrit at baseline, at the same one-month visit used for testosterone level titration, and again at three months. If values trend upward, even below 54%, consider therapeutic phlebotomy or dose reduction before reaching the guideline cutoff.

Polypharmacy Considerations

Men aged 50 to 64 take a median of four prescription medications, according to CDC National Health and Nutrition Examination Survey data 6. Jatenzo interacts with several commonly prescribed drug classes in ways that require dose adjustments or enhanced monitoring.

Anticoagulants (warfarin, direct oral anticoagulants): Testosterone can increase the effect of warfarin by displacing it from albumin binding sites and by altering clotting factor synthesis. The Jatenzo label recommends more frequent INR monitoring when co-prescribed with warfarin 1. For DOACs like apixaban or rivarelbana, the interaction risk is lower, but the polycythemia-driven thrombotic risk remains relevant.

Insulin and oral hypoglycemics: Testosterone may improve insulin sensitivity, potentially leading to hypoglycemia in men on sulfonylureas or insulin. Blood glucose monitoring should increase during the first three months of Jatenzo therapy 3.

Corticosteroids: Concurrent use can amplify fluid retention. Both testosterone and corticosteroids promote sodium reabsorption. In a man already taking prednisone for a chronic inflammatory condition, adding Jatenzo warrants closer attention to weight, peripheral edema, and blood pressure.

Antihypertensives: Given Jatenzo's boxed warning for blood pressure elevation, men already on antihypertensive regimens may need dose adjustments to their existing medications. Home blood pressure monitoring for two weeks after starting Jatenzo provides actionable data for medication titration.

Why the Oral Route Suits This Age Group

Older men weigh convenience, discretion, and safety differently than younger patients. The oral formulation addresses several practical barriers to TRT adherence in the 50-to-64 population.

Topical gels (e.g., AndroGel, Testim) carry a well-documented transference risk. An FDA communication warned that "secondary exposure to testosterone gel has been reported in children and women through skin-to-skin contact with men using these products" 7. For men in this age group who may live with partners, grandchildren, or aging parents, the transference issue is a legitimate safety concern, not a hypothetical one.

Injectable testosterone (cypionate or enanthate) requires either clinic visits for intramuscular injection every one to two weeks or self-injection, which some men find aversive or logistically difficult. Dr. Ronald Swerdloff, lead author of the key Jatenzo trial, noted that "an effective oral testosterone that avoids first-pass hepatotoxicity addresses a long-standing unmet need in male hypogonadism management" 2.

Jatenzo's twice-daily oral dosing eliminates needle disposal, injection-site reactions, and the pharmacokinetic peaks and troughs that characterize intramuscular regimens. The trade-off is strict meal adherence. For men with regular eating habits, this is manageable. For men who fast intermittently or eat erratically, other formulations may be better suited.

When to Reassess or Discontinue

Dose optimization is not permanent. Physiologic changes between 50 and 64 can shift the risk-benefit calculus over time.

The Endocrine Society guideline recommends reassessing the need for testosterone therapy at 3 to 6 months and then at least annually 3. Reassessment should include symptom review (energy, libido, mood, body composition), repeat serum testosterone, hematocrit, PSA, and lipid panel. The guideline states that clinicians should "discontinue testosterone therapy in men who do not show improvement in symptoms or signs after an adequate trial" 3.

PSA screening takes on added weight in this age group. While testosterone therapy does not cause prostate cancer based on current evidence, the Endocrine Society recommends against initiating TRT in men with a PSA above 4 ng/mL without urological evaluation, or in men with severe lower urinary tract symptoms (IPSS score above 19) 3. A baseline PSA and digital rectal exam should precede the first Jatenzo prescription. Repeat PSA at 3 to 6 months and annually thereafter.

Bone mineral density is another reason to track outcomes. A secondary analysis from the Testosterone Trials (TTrials) found that testosterone treatment in men aged 65 and older significantly increased volumetric bone mineral density of the spine and hip at 12 months compared to placebo 8. For men in the 50-to-64 range with osteopenia or risk factors for osteoporosis, documenting BMD response to TRT strengthens the clinical rationale for continuation.

Discontinuation should be gradual and monitored. Abrupt cessation can trigger symptomatic rebound hypogonadism, including fatigue, depression, and loss of libido. Tapering by one capsule strength every two to four weeks allows the hypothalamic-pituitary-gonadal axis to partially recover, though full endogenous recovery is unlikely in men with organic hypogonadism.

Practical Dosing Checklist for Clinicians

A structured approach reduces errors and ensures that older adults receive age-appropriate monitoring alongside their Jatenzo prescription.

1. Confirm the diagnosis of hypogonadism with two morning serum total testosterone levels below 300 ng/dL, drawn on separate days 3.
2. Obtain baseline labs: CBC with hematocrit, comprehensive metabolic panel, lipid panel, PSA, LH, FSH.
3. Assess cardiovascular risk: blood pressure, fasting glucose or HbA1c, and 10-year ASCVD risk score.
4. Screen for contraindications: polycythemia vera, untreated severe sleep apnea, uncontrolled heart failure (NYHA Class III/IV), PSA above 4 ng/mL without urological clearance.
5. Start Jatenzo 237 mg twice daily with meals containing at least 15 g of fat.
6. Draw serum total testosterone (trough) at approximately one month. Titrate per algorithm.
7. Recheck hematocrit and blood pressure at months 1, 3, and 6.
8. Repeat PSA at 3 to 6 months.
9. Schedule comprehensive reassessment at 6 months and annually thereafter.

Baseline hematocrit above 50% in a man with untreated sleep apnea warrants a sleep study before initiating Jatenzo, not after.